Guideline decision tool · Neurology
🧠

Ischemic Stroke / TIA Secondary Prevention — free guideline decision tool

From stroke mechanism and whether it is minor / intracranial large-artery stenosis, give the antithrombotic regimen with statin and BP targets. Instant, browser-side.

Open guideline tool →
Computed locally — no data uploaded. For licensed clinicians.
📋

Guideline-based

Implements the decision logic from published clinical guidelines.

🖥️

Runs in your browser

No installation. Enter the patient's values and get a guideline recommendation instantly.

🔒

Data stays local

Nothing is uploaded. Results are for licensed clinicians only.

Worked calculation

The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.

Stroke mechanismNon-cardioembolic (atherosclerotic/small-vessel/undetermined)
Minor stroke or high-risk TIA within 24hYes
Symptomatic severe intracranial large-artery stenosis (70–99%)Yes
Concomitant intra-/extracranial large-artery atherosclerosisYes

→Antithrombotic regimenClopidogrel + aspirin dual antiplatelet for 21 days then switch to single agent (CYP2C19 loss-of-function carriers may use ticagrelor + aspirin for 21 days then ticagrelor monotherapy)

  • Statin/LDL target:High-intensity statin, lower LDL-C to the current guideline target; add ezetimibe if not at goal (PCSK9i if needed)
  • Blood-pressure target:Due to intracranial large-artery stenosis: [pending update]
  • Other:Glycemic control (a GLP-1RA/SGLT2i with cardio-cerebrovascular benefit may be chosen in diabetes), smoking/alcohol cessation, exercise and weight control; assess CEA or CAS for symptomatic carotid stenosis 70–99%
Stroke mechanismCardioembolic (AF, etc.)
Minor stroke or high-risk TIA within 24hNo
Symptomatic severe intracranial large-artery stenosis (70–99%)No
Concomitant intra-/extracranial large-artery atherosclerosisNo

→Antithrombotic regimenOral anticoagulation (NOAC preferred for AF and other cardioembolic causes; warfarin for mechanical valve or moderate-severe mitral stenosis)

  • Statin/LDL target:If non-cardioembolic and LDL-C ≥ 2.6 give high-intensity statin; with large-artery atherosclerosis the target is < 1.8
  • Blood-pressure target:Lower [pending update] if tolerated
  • Other:Glycemic control (a GLP-1RA/SGLT2i with cardio-cerebrovascular benefit may be chosen in diabetes), smoking/alcohol cessation, exercise and weight control; assess CEA or CAS for symptomatic carotid stenosis 70–99%

Common questions

What is Ischemic Stroke / TIA Secondary Prevention?

From stroke mechanism and whether it is minor / intracranial large-artery stenosis, give the antithrombotic regimen with statin and BP targets. Instant, browser-side.

How is Ischemic Stroke / TIA Secondary Prevention calculated? What is the core formula?

Non-cardioembolic → antiplatelet (single agent usually; clopidogrel + aspirin for 21 days after minor stroke or high-risk TIA; dual then single for symptomatic intracranial stenosis 70–99%). Cardioembolic (AF) → anticoagulation (NOAC preferred). LDL lowering to the current guideline target with large-artery atherosclerosis; BP if tolerated [pending update] with intracranial stenosis).

When is Ischemic Stroke / TIA Secondary Prevention used?

Direction for secondary prevention after ischemic stroke or TIA.

What are the key clinical points for Ischemic Stroke / TIA Secondary Prevention?

Short-term dual antiplatelet (21 days) benefits minor stroke / high-risk TIA; longer dual suits symptomatic intracranial large-artery stenosis, then de-escalate to single agent. CYP2C19 loss-of-function carriers may use ticagrelor + aspirin in place of clopidogrel-based dual therapy. High-intensity statin with (add ezetimibe, then PCSK9i, if not at goal) for large-artery atherosclerosis. Assess CEA/CAS for symptomatic carotid stenosis 70–99%; control glucose, stop smoking, exercise.

What are the limits and cautions when using Ischemic Stroke / TIA Secondary Prevention?

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

Does Ischemic Stroke / TIA Secondary Prevention upload patient data? Where is it calculated?

Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.

How is Ischemic Stroke / TIA Secondary Prevention calculated in practice? Can you show a worked example?

Inputs: Stroke mechanism Non-cardioembolic (atherosclerotic/small-vessel/undetermined), Minor stroke or high-risk TIA within 24h Yes, Symptomatic severe intracranial large-artery stenosis (70–99%) Yes, Concomitant intra-/extracranial large-artery atherosclerosis Yes → Result: Antithrombotic regimen Clopidogrel + aspirin dual antiplatelet for 21 days then switch to single agent (CYP2C19 loss-of-function carriers may use ticagrelor + aspirin for 21 days then ticagrelor monotherapy)(Statin/LDL target: High-intensity statin, lower LDL-C to the current guideline target; add ezetimibe if not at goal (PCSK9i if needed), Blood-pressure target: Due to intracranial large-artery stenosis: [pending update] , Other: Glycemic control (a GLP-1RA/SGLT2i with cardio-cerebrovascular benefit may be chosen in diabetes), smoking/alcohol cessation, exercise and weight control; assess CEA or CAS for symptomatic carotid stenosis 70–99%) Inputs: Stroke mechanism Cardioembolic (AF, etc.), Minor stroke or high-risk TIA within 24h No, Symptomatic severe intracranial large-artery stenosis (70–99%) No, Concomitant intra-/extracranial large-artery atherosclerosis No → Result: Antithrombotic regimen Oral anticoagulation (NOAC preferred for AF and other cardioembolic causes; warfarin for mechanical valve or moderate-severe mitral stenosis)(Statin/LDL target: If non-cardioembolic and LDL-C ≥ 2.6 give high-intensity statin; with large-artery atherosclerosis the target is < 1.8, Blood-pressure target: Lower [pending update] if tolerated, Other: Glycemic control (a GLP-1RA/SGLT2i with cardio-cerebrovascular benefit may be chosen in diabetes), smoking/alcohol cessation, exercise and weight control; assess CEA or CAS for symptomatic carotid stenosis 70–99%)

🧠

Run Ischemic Stroke / TIA Secondary Prevention now

From stroke mechanism and whether it is minor / intracranial large-artery stenosis, give the antithrombotic regimen with statin and BP targets. Instant, browser-side.

Open guideline tool →

For licensed clinicians. Not a substitute for clinical judgement.

Share on XLinkedInWhatsAppEmail

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Related guideline tools

For use by licensed clinicians and clinical researchers. Computed locally in your browser — no data is uploaded. Not a substitute for clinical judgement.

Water does not race to be first — it strives only to flow on, unbroken

Yuan Doctor
Tertiary-hospital clinical team · local compute · no upload
© 2026 Yuan Doctor · www.yuandoctor.com · Developed & reviewed by a tertiary-hospital clinical team